{"id":"alzt-op1b","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALZT-OP1b targets multiple pathways implicated in Alzheimer's disease neurodegeneration, including tau protein aggregation and neuroinflammatory processes. By addressing these underlying disease mechanisms rather than amyloid alone, the drug aims to provide disease-modifying benefits in early symptomatic Alzheimer's disease patients.","oneSentence":"ALZT-OP1b is a small molecule that modulates tau pathology and neuroinflammation to slow cognitive decline in Alzheimer's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:01.283Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"}]},"trialDetails":[{"nctId":"NCT04570644","phase":"PHASE1","title":"Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2020-08-28","conditions":"Healthy Volunteers, Alzheimer Disease","enrollment":56},{"nctId":"NCT02547818","phase":"PHASE3","title":"Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-09-15","conditions":"Alzheimer's Disease","enrollment":620},{"nctId":"NCT02482324","phase":"PHASE1","title":"Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-06","conditions":"Healthy Volunteers","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ibuprofen","Ibuprofen"],"phase":"phase_3","status":"active","brandName":"ALZT-OP1b","genericName":"ALZT-OP1b","companyName":"AZTherapies, Inc.","companyId":"aztherapies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALZT-OP1b is a treatment being studied in a Phase 1 clinical trial for Alzheimer's Disease. The study is a randomized, open-labeled pharmacokinetic study of ALZT-OP1 in normal healthy volunteers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}